Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 56
Appendix B Speakers and Panelists Susan Alpert, M.D., Ph.D. Director of Device Evaluation Center for Devices and Radiological Health Food and Drug Administration Robert Califf, M.D. Director Duke Clinical Research Institute Michaele C. Christian, M.D. Associate Director, Cancer Therapy Evaluation Program Division of Cancer Treatment National Cancer Institute Michael Clayman, M.D. Vice President Cardiovascular Research and Clinical Investigations Lilly Research Laboratories Eli Lilly and Company Susan Ellenberg, Ph.D. Director Division of Biostatistics and Epidemiolgy Center for Biologics Evaluation and Research Food and Drug Administration Ronald Estabrook, Ph.D. Professor of Biochemistry University of Texas Southwestern Medical Center William Fairweather, Ph.D. Associate Director Office of Epidemiology and Biostatistics Food and Drug Administration Frank L. Hurley, Ph.D. Chief Science Officer Quintiles Transnational Corporation
OCR for page 57
Charma Konnor Director Bioresearch Monitoring Division Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Kiyoshi Kuromiya Critical Path AIDS Project David Lepay, M.D., Ph.D. Director Division of Scientific Investigations Food and Drug Administration Robert Levy, M.D. Senior Vice President, Science and Technology American Home Products Wyeth-Ayerst Research Murray Lumpkin M.D. Deputy Director for Review Management Center for Drug Evaluation and Research Food and Drug Administration Michael McGarvey, M.D. Chief Medical Officer Blue Cross and Blue Shield of New Jersey, Inc. Roger Meyer, M.D. Senior Consultant Division of Biomedical and Health Sciences Research American Association of Medical Colleges Kristin O'Connor, M.P.H. Director, Data Management Boehringer Ingleheim Pharmaceuticals, Inc. Nicholas Pelliccione, Ph.D. Senior Director Worldwide Regulatory Affairs Schering Plough Jim Phillips, Ph.D. Senior Director for Biostatistics Quintiles Transnational Corp. John Schultz, Ph.D. Vice President General Manager Neuroclinical Trials Center University of Virginia Eleanor Segal, M.D. Senior Director Drug Safety and Clinical Quality Assurance Chiron Corporation Kenneth I. Shine, M.D. President Institute of Medicine Jay Siegel, M.D. Director Office of Therapeutics Research and Review Center for Biologics Evaluation and Research Food and Drug Administration Whaijen Soo, M.D., Ph.D. Vice President, Clinical Sciences Roche Pharmaceuticals Hoffmann-La Roche, Inc. Frances Visco, J.D. President National Breast Cancer Coalition
OCR for page 58
William Waggoner, Ph.D., FAACT Chairman Essex Institutional Review Board, Inc. Janet Woodcock, M.D. Director Center for Drug Evaluation and Research Food and Drug Administration Stan Woollen Deputy Director Division of Scientific Investigations Center for Drug Evaluation and Research Food and Drug Administration
Representative terms from entire chapter: